CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows From Operating Activities:
Net income (loss)	$ (39,300)	$ 119,706
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	11,953	9,417
Realized gain (loss) on marketable securities	(11)	293
Gain upon divestiture of Pediatric Priority Review Voucher	0	(140,004)
Gain upon divestiture of assets to Turing Pharmaceuticals	0	(914)
Deferred income tax benefit	(10,999)	(11,791)
Interest income from notes receivable	(1,605)	0
Legal fee settlement	5,212	0
Non-cash interest expense	1,551	1,818
Amortization of premiums on marketable securities	853	0
Amortization of debt discount and deferred financing costs	491	1,175
Lease liability	0	32
Loss on early retirement of debt	0	4,151
Impairment of intangible assets	0	4,710
Loss on disposal of fixed assets	0	112
Legal accrual reversal	(2,967)	0
Bargain purchase gain	0	(49,063)
Share based compensation	22,034	18,748
Derivative financial instruments, warrants, issued, recorded in interest expense	0	1,050
Change in estimated fair value of liability classified warrants	4,849	36,180
Change in estimated fair value of contingent consideration	10,741	7,026
Payments related to change in fair value of contingent consideration	(772)	(203)
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable	(2,486)	(5,540)
Inventory	(712)	(1,284)
Prepaid expenses and other current assets	(822)	(1,912)
Accounts payable and accrued expenses	3,278	(1,172)
Income taxes payable	3,879	9,628
Net cash provided by operating activities	5,167	2,163
Cash Flows From Investing Activities:
Purchase of fixed assets	(61)	(35)
Cash paid for intangible assets	(7,632)	(5,271)
Proceeds from the sale/maturity of marketable securities	92,609	4,977
Purchase of marketable securities	(152,016)	(94,793)
Proceeds from maturity of note receivable	47,500	0
Security deposits	(115)	0
Cash received upon divestiture of asset	0	148,411
Cash paid upon acquisition, net of cash acquired	(500)	(33,430)
Net cash provided by (used in) investing activities	(20,215)	19,859
Cash Flows From Financing Activities:
Payment of guaranteed minimum royalty	(1,500)	(1,500)
Proceeds from exercise of warrants	5,998	4,372
Payment of other liability	(750)	(1,000)
Proceeds from exercise of stock options	2,225	5,237
Excess benefit related to stock compensation	(439)	834
Repayment of credit facility	0	(45,000)
Proceeds received from issuance of common stock	0	149,454
Financing costs from issuance of common stock	0	(9,500)
Net cash provided by financing activities	1,195	100,370
Effect of exchange rate changes on cash	(57)	0
Net change in cash	(13,910)	122,392
Cash, beginning of year	37,805	18,204
Cash, end of period	23,895	140,596
Manchester
Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration	(3,257)	(2,220)
Asklepion
Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration	$ (1,082)	$ (307)